SS Innovations International (NASDAQ: SSII) has reported record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from $10 million in the same period last year, according to a press release issued by the company. The growth was fueled by a 30.4% rise in installations of its SSi Mantra surgical robotic system, which reached 30 units during the quarter. Gross profit climbed 20% to $7.1 million, with a gross margin of 50.9%. The company reported a net loss of $2.7 million, or $0.01 per diluted share, compared to a net loss of $0.3 million in the prior year.
For the first half of 2026, revenue surged 65.6% to $25 million, and SSi Mantra installations increased 47.4% to 56 units. As of June 30, SS Innovations had $13.6 million in cash and cash equivalents, no long-term debt, and a cumulative installed base of 224 SSi Mantra systems across 12 countries. The company also reported 12,272 cumulative procedures using the SSi Mantra, including 175 telesurgeries. Notably, SS Innovations completed a robotic telesurgery spanning more than 13,600 miles between Colombia and India, demonstrating the system's remote capabilities.
The company expects the U.S. Food and Drug Administration (FDA) to complete its review of the SSi Mantra's 510(k) premarket notification by the end of the first quarter of 2027. Additionally, SS Innovations believes it can obtain European Union CE marking certification by the end of 2026. These regulatory milestones are critical for expanding the system's availability in major markets.
The strong financial performance and operational milestones underscore SS Innovations' commitment to making robotic surgery affordable and accessible globally. With a focus on innovation and expansion, the company is well-positioned to capitalize on the growing demand for minimally invasive surgical solutions. The record revenue and system installations reflect the increasing adoption of the SSi Mantra, which supports a variety of procedures including cardiac surgery. As the company progresses toward regulatory approvals and expands its global footprint, it aims to disrupt the surgical robotics market with its cost-effective and user-friendly technology.
For more details, the full press release is available at https://ibn.fm/nTMso. The latest news and updates relating to SSII can be found in the company's newsroom at https://ibn.fm/SSII.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company's filings with the SEC. These statements are based on information available as of the date of this release, and the company undertakes no duty to update them unless required by law.
